Table of Content


1 Markets
1.1 Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.1.3 Key Findings
1.1.4 Market Growth Scenario
1.1.4.1 Realistic Growth
1.1.4.2 Optimistic Growth
1.1.4.3 Pessimistic/Conservative Growth
1.2 Industry Outlook
1.2.1 Technology Landscape
1.2.1.1 Key Trends
1.2.1.1.1 Integration of Hardware and Software Solutions for Imaging
1.2.1.1.2 Investigation of Ensemble Models that Involve Multiple Classifiers such as Biomarkers and Patient Features
1.2.1.1.3 Rising Preference for Portable Brain Scanners and Wearables
1.2.1.1.4 Integration of Augmented Reality with Medical Imaging
1.2.1.1.5 Increased Focus on Targeting the Pediatric Population
1.2.2 Opportunity Assessment
1.2.2.1 Short-Term Potential
1.2.2.2 Long-Term Potential
1.2.3 Product Benchmarking
1.2.4 Patent Analysis
1.2.4.1 Patent Analysis by Country/Cluster
1.2.4.2 Patent Analysis by Year
1.3 Impact of COVID-19 on the Global Brain Disease Modalities and Software Market
1.3.1 Impact on Facilities
1.3.2 Impact on Modalities Adoption
1.3.3 Impact on Market Size
1.3.3.1 Pre-COVID-19 Phase
1.3.3.2 During-COVID-19 Phase
1.3.3.3 Post-COVID-19 Phase
1.4 Business Dynamics
1.4.1 Impact Analysis
1.4.2 Business Drivers
1.4.2.1 Increasing Prevalence of Neurological Disorders
1.4.2.2 Rising AI Integration in the Field of Medical Imaging
1.4.2.3 Increasing Demand for Safer and Non-Invasive Devices for Medical Imaging
1.4.3 Business Restraints
1.4.3.1 High Upfront Cost of Imaging Devices
1.4.3.2 Declining Availability of Helium
1.4.4 Business Opportunities
1.4.4.1 Integration of Imaging Solutions with Novel Biomarkers to Enable Diagnosis of a Wider Range of Neurological Disorders
1.4.4.2 Integration of 3D Amplified MRI, a New Technological Advancement

2 Application
2.1 Brain Disease Modalities and Software Market (by Indication)
2.1.1 Opportunity Assessment
2.1.2 Growth Share Matrix
2.1.3 Brain Diseases
2.1.3.1 Patient Volume
2.1.3.2 Brain and Central Nervous System Cancer
2.1.3.2.1 Market Trend
2.1.3.2.2 Market Size and Forecast
2.1.3.2.3 Examination Process
2.1.3.2.4 Key Modalities Analysis
2.1.3.3 Idiopathic Epilepsy
2.1.3.3.1 Market Trend
2.1.3.3.2 Market Size and Forecast
2.1.3.3.3 Examination Process
2.1.3.3.4 Key Modalities Analysis
2.1.3.4 Ischemic Stroke
2.1.3.4.1 Market Trend
2.1.3.4.2 Market Size and Forecast
2.1.3.4.3 Examination Process
2.1.3.4.4 Key Modalities Analysis
2.1.3.5 Other Brain Diseases
2.1.3.5.1 Market Trend
2.1.3.5.2 Market Size and Forecast
2.1.3.5.3 Examination Process
2.1.3.5.4 Key Modalities Analysis
2.1.4 Neurodegenerative Diseases
2.1.4.1 Patient Volume
2.1.4.2 Key Examination Process for Disease Confirmation
2.1.4.3 Alzheimer’s Disease
2.1.4.3.1 Market Trend
2.1.4.3.2 Market Size and Forecast
2.1.4.3.3 Medical Bill and Fee
2.1.4.3.3.1 North America
2.1.4.3.3.2 Europe
2.1.4.3.3.3 Asia-Pacific
2.1.4.3.3.4 Rest-of-the-World
2.1.4.4 Multiple Sclerosis
2.1.4.4.1 Market Trend
2.1.4.4.2 Market Size and Forecast
2.1.4.4.3 Medical Bill and Fee
2.1.4.4.3.1 North America
2.1.4.4.3.2 Europe
2.1.4.4.3.3 Asia-Pacific
2.1.4.4.3.4 Rest-of-the-World
2.1.4.5 Parkinson’s Disease
2.1.4.5.1 Market Trend
2.1.4.5.2 Market Size and Forecast
2.1.4.5.3 Medical Bill and Fee
2.1.4.5.3.1 North America
2.1.4.5.3.2 Europe
2.1.4.5.3.3 Asia-Pacific
2.1.4.5.3.4 Rest-of-the-World
2.1.4.6 Motor Neuron Disease
2.1.4.6.1 Market Trend
2.1.4.6.2 Market Size and Forecast
2.1.4.6.3 Medical Bill and Fee
2.1.4.6.3.1 North America
2.1.4.6.3.2 Europe
2.1.4.6.3.3 Asia-Pacific
2.1.4.6.3.4 Rest-of-the-World
2.1.4.7 Other Neurodegenerative Diseases
2.1.4.7.1 Market Trend
2.1.4.7.2 Market Size and Forecast
2.1.4.7.3 Medical Bill and Fee
2.1.4.7.3.1 North America
2.1.4.7.3.2 Europe
2.1.4.7.3.3 Asia-Pacific
2.1.4.7.3.4 Rest-of-the-World
2.2 Global Brain Disease Modalities and Software Market (by Patient Type)
2.2.1 Opportunity Assessment
2.2.2 Adults
2.2.2.1 Market Trends
2.2.2.2 Market Size and Forecast
2.2.3 Pediatrics and Infants
2.2.3.1 Market Trends
2.2.3.2 Market Size and Forecast
2.3 Global Brain Disease Modalities and Software Market (by End User)
2.3.1 Opportunity Assessment
2.3.2 Hospitals and Clinics
2.3.3 Diagnostic Imaging Centers
2.3.4 Ambulatory Surgery Centers

3 Products
3.1 Brain Disease Modalities and Software Market (by Product)
3.1.1 Opportunity Assessment
3.1.2 Growth Share Matrix
3.1.3 Brain Modalities
3.1.3.1 Market Size and Forecast
3.1.3.2 by Type
3.1.3.2.1 PET Devices
3.1.3.2.2 PET-CT
3.1.3.2.3 PET-MRI
3.1.3.2.4 CT Devices
3.1.3.2.5 MRI Devices
3.1.4 Brain Analysis Software
3.1.4.1 Market Trends
3.1.4.1.1 North America
3.1.4.1.2 Europe
3.1.4.1.3 Asia-Pacific
3.1.4.1.4 Rest-of-the-World
3.1.4.2 Pricing Analysis
3.1.4.3 Vendor Trends
3.1.4.3.1 Market Share Analysis
3.1.4.3.2 Skills Analysis
3.1.4.3.3 Purpose/Application Analysis
3.1.4.3.4 Target Disease Analysis
3.1.4.3.5 Modality Analysis
3.1.4.3.6 Analytical Report Status
3.1.4.3.7 Regulatory Status Analysis

4 Region
4.1 North America Brain Disease Modalities and Software Market
4.1.1 Market
4.1.1.1 Regulatory Framework
4.1.1.2 Opportunity Assessment
4.1.1.3 Market Dynamics
4.1.1.3.1 Impact Analysis
4.1.1.4 Sizing and Forecast Analysis
4.1.2 Application
4.1.2.1 North America Brain Disease Modalities and Software Market (by Indication)
4.1.2.2 North America Brain Disease Modalities and Software Market (by Patient Type)
4.1.2.3 North America Brain Disease Modalities and Software Market (by End User)
4.1.3 Product
4.1.3.1 North America Brain Disease Modalities and Software Market (by Product)
4.1.4 North America Brain Disease Modalities and Software Market (by Country)
4.1.4.1 U.S.
4.1.4.2 Canada
4.2 Europe Brain Disease Modalities and Software Market
4.2.1 Market
4.2.1.1 Regulatory Framework
4.2.1.2 Opportunity Assessment
4.2.1.3 Market Dynamics
4.2.1.3.1 Impact Analysis
4.2.1.4 Sizing and Forecast Analysis
4.2.2 Application
4.2.2.1 Europe Brain Disease Modalities and Software Market (by Indication)
4.2.2.2 Europe Brain Disease Modalities and Software Market (by Patient Type)
4.2.2.3 Europe Brain Disease Modalities and Software Market (by End User)
4.2.3 Product
4.2.3.1 Europe Brain Disease Modalities and Software Market (by Product)
4.2.4 Europe Brain Disease Modalities and Software Market (by Country)
4.2.4.1 Germany
4.2.4.2 U.K.
4.2.4.3 France
4.2.4.4 Italy
4.2.4.5 Spain
4.2.4.6 Rest-of-Europe
4.3 Asia-Pacific Brain Disease Modalities and Software Market
4.3.1 Market
4.3.1.1 Regulatory Framework
4.3.1.2 Opportunity Assessment
4.3.1.3 Market Dynamics
4.3.1.3.1 Impact Analysis
4.3.1.4 Sizing and Forecast Analysis
4.3.2 Application
4.3.2.1 Asia-Pacific Brain Disease Modalities and Software Market (by Indication)
4.3.2.2 Asia-Pacific Brain Disease Modalities and Software Market (by Patient Type)
4.3.2.3 Asia-Pacific Brain Disease Modalities and Software Market (by End User)
4.3.3 Product
4.3.3.1 Asia-Pacific Brain Disease Modalities and Software Market (by Product)
4.3.4 Asia-Pacific Brain Disease Modalities and Software Market (by Country)
4.3.4.1 Japan
4.3.4.2 China
4.3.4.3 India
4.3.4.4 South Korea
4.3.4.5 Australia and New Zealand
4.3.4.6 Rest-of-Asia-Pacific
4.4 Rest-of-the-World Brain Disease Modalities and Software Market
4.4.1 Market
4.4.1.1 Regulatory Framework
4.4.1.2 Opportunity Assessment
4.4.1.3 Market Dynamics
4.4.1.3.1 Impact Analysis
4.4.1.4 Sizing and Forecast Analysis
4.4.2 Application
4.4.2.1 Rest-of-the-World Brain Disease Modalities and Software Market (by Indication)
4.4.2.2 Rest-of-the-World Brain Disease Modalities and Software Market (by Patient Type)
4.4.2.3 Rest-of-the-World Brain Disease Modalities and Software Market (by End User)
4.4.3 Product
4.4.3.1 Rest-of-the-World Brain Disease Modalities and Software Market (by Product)
4.4.4 Rest-of-the-World Brain Disease Modalities and Software Market (by Region)
4.4.4.1 Latin America
4.4.4.2 Middle East and Africa
5 Markets - Competitive Benchmarking & Company Profiles
5.1 Competitive Benchmarking and Company Profiles
5.1.1 Competitive Landscape
5.1.1.1 Key Strategies and Developments
5.1.1.1.1 Partnerships, Alliances, and Business Expansions
5.1.1.1.2 Funding Activities
5.1.1.1.3 New Offerings
5.1.1.1.4 Mergers and Acquisitions
5.1.1.1.5 Regulatory and Legal Activities
5.2 Market Share Analysis
5.3 Company Profiles
5.3.1 Brain Disease Modalities and Software Companies
5.3.1.1 United Imaging Healthcare Co., Ltd.
5.3.1.1.1 Company Overview
5.3.1.1.2 Role of United Imaging Healthcare Co., Ltd. in the Global Brain Disease Modalities and Software Market
5.3.1.1.3 Product Portfolio and Offerings
5.3.1.1.4 Recent Developments
5.3.1.1.5 SWOT Analysis
5.3.1.2 Koninklijke Philips N.V.
5.3.1.2.1 Company Overview
5.3.1.2.2 Role of Koninklijke Philips N.V. in the Global Brain Disease Modalities and Software Market
5.3.1.2.3 Product Portfolio and Offerings
5.3.1.2.4 Financials
5.3.1.2.5 SWOT Analysis
5.3.1.3 General Electric Company
5.3.1.3.1 Company Overview
5.3.1.3.2 Role of General Electric Company in the Global Brain Disease Modalities and Software Market
5.3.1.3.3 Product Portfolio and Offerings
5.3.1.3.4 Financials
5.3.1.3.5 SWOT Analysis
5.3.1.4 Canon, Inc.
5.3.1.4.1 Company Overview
5.3.1.4.2 Role of Canon, Inc. in the Global Brain Disease Modalities and Software Market
5.3.1.4.3 Product Portfolio and Offerings
5.3.1.4.4 Recent Developments
5.3.1.4.5 Financials
5.3.1.4.6 SWOT Analysis
5.3.1.5 Siemens Healthineers AG
5.3.1.5.1 Company Overview
5.3.1.5.2 Role of Siemens Healthineers AG in the Global Brain Disease Modalities and Software Market
5.3.1.5.3 Product Portfolio and Offerings
5.3.1.5.4 Financials
5.3.1.5.5 Recent Developments
5.3.1.5.6 SWOT Analysis
5.3.1.6 Vuno Co., Ltd.
5.3.1.6.1 Company Overview
5.3.1.6.2 Role of Vuno Co., Ltd. in the Global Brain Disease Modalities and Software Market
5.3.1.6.3 Product Portfolio and Offerings
5.3.1.6.4 Recent Developments
5.3.1.6.5 SWOT Analysis
5.3.1.7 Fujifilm Holdings Corporation
5.3.1.7.1 Company Overview
5.3.1.7.2 Role of Fujifilm Holdings Corporation in the Global Brain Disease Modalities and Software Market
5.3.1.7.3 Product Portfolio
5.3.1.7.4 Financials
5.3.1.7.5 Recent Developments
5.3.1.7.6 SWOT Analysis
5.3.1.8 Aspect Imaging
5.3.1.8.1 Company Overview
5.3.1.8.2 Role of Aspect Imaging in the Global Brain Disease Modalities and Software Market
5.3.1.8.3 Product Portfolio and Offerings
5.3.1.8.4 SWOT Analysis
5.3.2 Brain Imaging Software Companies
5.3.2.1 IXICO
5.3.2.1.1 Company Overview
5.3.2.1.2 Role of IXICO in the Global Brain Disease Modalities and Software Market
5.3.2.1.3 Product Portfolio and Offerings
5.3.2.1.4 Financials
5.3.2.1.5 Recent Developments
5.3.2.1.6 SWOT Analysis
5.3.2.2 QMENTA
5.3.2.2.1 Company Overview
5.3.2.2.2 Role of QMENTA in the Global Brain Disease Modalities and Software Market
5.3.2.2.3 Product Portfolio and Offerings
5.3.2.2.4 SWOT Analysis
5.3.2.3 Cortechs.ai
5.3.2.3.1 Company Overview
5.3.2.3.2 Role of Cortechs.ai in the Global Brain Disease Modalities and Software Market
5.3.2.3.3 Product Portfolio and Offerings
5.3.2.3.4 Recent Developments
5.3.2.3.5 SWOT Analysis
5.3.2.4 Quantib
5.3.2.4.1 Company Overview
5.3.2.4.2 Role of Quantib in the Global Brain Disease Modalities and Software Market
5.3.2.4.3 Product Portfolio and Offerings
5.3.2.4.4 Recent Developments
5.3.2.4.5 SWOT Analysis
5.3.2.5 Brainomix
5.3.2.5.1 Company Overview
5.3.2.5.2 Role of Brainomix in the Global Brain Disease Modalities and Software Market
5.3.2.5.3 Product Portfolio and Offerings
5.3.2.5.4 Recent Developments
5.3.2.5.5 SWOT Analysis
5.3.2.6 Qure.AI
5.3.2.6.1 Company Overview
5.3.2.6.2 Role of Qure.AI in the Global Brain Disease Modalities and Software Market
5.3.2.6.3 Product Portfolio and Offerings
5.3.2.6.4 Recent Developments
5.3.2.6.5 SWOT Analysis
5.3.2.7 Imaging Biometrics, LLC
5.3.2.7.1 Company Overview
5.3.2.7.2 Role of Imaging Biometrics, LLC in the Global Brain Disease Modalities and Software Market
5.3.2.7.3 Product Portfolio and Offerings
5.3.2.7.4 Recent Developments
5.3.2.7.5 SWOT Analysis
5.3.2.8 A.I. Analysis, Inc.
5.3.2.8.1 Company Overview
5.3.2.8.2 Role of A.I. Analysis, Inc. in the Global Brain Disease Modalities and Software Market
5.3.2.8.3 Product Portfolio and Offerings
5.3.2.8.4 SWOT Analysis

6 Research Methodology
6.1 Data Collection and Analysis
6.2 Data Sources
6.2.1 Primary Data Sources
6.2.2 Secondary Data Sources
6.3 Data Triangulation
6.4 Market Estimation
6.5 Forecast Period Selection Criteria
6.6 Assumptions and Limitations
List of Figures
Figure 1: Global Brain Disease Modalities and Software Market, Impact Analysis
Figure 2: Market Size Forecast (by Region), 2021 and 2031
Figure 3: Global Brain Disease Modalities and Software Market, Overall Coverage
Figure 4: Global Brain Disease Modalities and Software Market, Potential Forecast Scenarios
Figure 5: Global Brain Disease Modalities and Software Market Size and Growth Potential (Realistic Scenario), $Million, 2020-2031
Figure 6: Global Brain Disease Modalities and Software Market Size and Growth Potential (Optimistic Scenario), $Million, 2020-2031
Figure 7: Global Brain Disease Modalities and Software Market Size and Growth Potential (Pessimistic Scenario/Conservative Growth), $Million, 2020-2031
Figure 8: Global Brain Disease Modalities and Software Market, Key Technology Trends
Figure 9: Global Brain Disease Modalities and Software Market Key Trends, Short-Term Potential
Figure 10: Global Brain Disease Modalities and Software Market Key Trends, Long-Term Potential
Figure 11: Global Brain Disease Modalities and Software Market Patent Analysis (by Country/Cluster), 2018-2021
Figure 12: Global Brain Disease Modalities and Software Market Patent Analysis (by Year), 2018-2021
Figure 13: Global Brain Disease Modalities and Software Market, Pre-COVID-19 Phase, $Million, 2018-2031
Figure 14: Global Brain Disease Modalities and Software Market, Impact Analysis
Figure 15: Global Brain Disease Modalities and Software Market, Prevalence of Brain Diseases, 2010, 2015, and 2019
Figure 16: Global Brain Disease Modalities and Software Market, Prevalence of Neurodegenerative Diseases, 2010, 2015, and 2019
Figure 17: Global Brain Disease Modalities and Software Market, Role of AI in Medical Imaging
Figure 18: Global Brain Disease Modalities and Software Market (by Indication)
Figure 19: Global Brain Disease Modalities and Software Market Incremental Opportunity (by Indication), $Million, 2021-2031
Figure 20: Global Brain Disease Modalities and Software Market, Growth Share Matrix (by Indication), 2021-2031
Figure 21: Global Brain Disease Modalities and Software Market (Brain and Central Nervous System Cancer), $Million, 2020-2031
Figure 22: Global Brain Disease Modalities and Software Market (Idiopathic Epilepsy), $Million, 2020-2031
Figure 23: Global Brain Disease Modalities and Software Market (Ischemic Stroke), $Million, 2020-2031
Figure 24: Global Brain Disease Modalities and Software Market (Other Brain Diseases), $Million, 2020-2031
Figure 25: Global Brain Disease Modalities and Software Market (Alzheimer?s Disease), $Million, 2020-2031
Figure 26: Global Brain Disease Modalities and Software Market (Multiple Sclerosis), $Million, 2020-2031
Figure 27: Global Brain Disease Modalities and Software Market (Parkinson?s Disease), $Million, 2020-2031
Figure 28: Global Brain Disease Modalities and Software Market (Motor Neuron Disease), $Million, 2020-2031
Figure 29: Global Brain Disease Modalities and Software Market (Other Neurodegenerative Diseases), $Million, 2020-2031
Figure 30: Global Brain Disease Modalities and Software Market (by Patient Type)
Figure 31: Global Brain Disease Modalities and Software Market Incremental Opportunity (by Patient Type), $Million, 2021-2031
Figure 32: Global Brain Disease Modalities and Software Market (Adults), $Million, 2020-2031
Figure 33: Global Brain Disease Modalities and Software Market (Pediatrics and Infants), $Million, 2020-2031
Figure 34: Global Brain Disease Modalities and Software Market (by End User)
Figure 35: Global Brain Disease Modalities and Software Market, Incremental Opportunity (by End User), $Million, 2021-2031
Figure 36: Global Brain Disease Modalities and Software Market (Hospitals and Clinics), $Million, 2020-2031
Figure 37: Global Brain Disease Modalities and Software Market (Diagnostic Imaging Centers), $Million, 2020-2031
Figure 38: Global Brain Disease Modalities and Software Market (Ambulatory Surgery Centers), $Million, 2020-2031
Figure 39: Global Brain Disease Modalities and Software Market (by Product)
Figure 40: Global Brain Disease Modalities and Software Market, Incremental Opportunity (by Product), $Million, 2021-2031
Figure 41: Global Brain Disease Modalities and Software Market, Growth Share Matrix (by Product), 2021-2031
Figure 42: Global Brain Disease Modalities and Software Market (by Brain Modalities), $Million, 2020-2031
Figure 43: North America Brain Disease Modalities and Software Market, PET Devices, $Million, 2020-2031
Figure 44: North America Brain Disease Modalities and Software Market, PET-CT, $Million, 2020-2031
Figure 45: North America Brain Disease Modalities and Software Market, PET-MRI, $Million, 2020-2031
Figure 46: North America Brain Disease Modalities and Software Market, CT Devices, $Million, 2020-2031
Figure 47: North America Brain Disease Modalities and Software Market, MRI Devices, $Million, 2020-2031
Figure 48: North America Brain Disease Modalities and Software Market, Brain Analysis Software, $Million, 2020-2031
Figure 49: Global Brain Analysis Software Market, Company Revenue Share Analysis, $Million, 2021
Figure 50: Global Brain Disease Modalities and Software Market (by Region), $Million, 2020-2031
Figure 51: North America Brain Disease Modalities and Software Market, Incremental Revenue Opportunity (by Country), $Million, 2021-2031
Figure 52: North America Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 53: North America Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
Figure 54: North America Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
Figure 55: North America Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
Figure 56: North America Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
Figure 57: North America Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
Figure 58: North America Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
Figure 59: North America Brain Disease Modalities and Software Market (by Country), $Million, 2021 and 2031
Figure 60: U.S. Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 61: Canada Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 62: Europe Brain Disease Modalities and Software Market Incremental Revenue Opportunity (by Country), $Million, 2021-2031
Figure 63: Europe Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 64: Europe Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
Figure 65: Europe Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
Figure 66: Europe Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
Figure 67: Europe Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
Figure 68: Europe Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
Figure 69: Europe Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
Figure 70: Europe Brain Disease Modalities and Software Market (by Country), $Million, 2021 and 2031
Figure 71: Germany Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 72: U.K. Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 73: France Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 74: Italy Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 75: Spain Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 76: Rest-of-Europe Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 77: Asia-Pacific Brain Disease Modalities and Software Market, Incremental Revenue Opportunity (by Country), $Million, 2021-2031
Figure 78: Asia-Pacific Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 79: Asia-Pacific Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
Figure 80: Asia-Pacific Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
Figure 81: Asia-Pacific Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
Figure 82: Asia-Pacific Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
Figure 83: Asia-Pacific Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
Figure 84: Asia-Pacific Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
Figure 85: Asia-Pacific Brain Disease Modalities and Software Market (by Country), $Million, 2021 and 2031
Figure 86: Japan Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 87: China Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 88: India Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 89: South Korea Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 90: Australia and New Zealand Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 91: Rest-of-Asia-Pacific Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 92: Rest-of-the-World Brain Disease Modalities and Software Market Incremental Revenue Opportunity (by Country), $Million, 2021-2031
Figure 93: Rest-of-the-World Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 94: Rest-of-the-World Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
Figure 95: Rest-of-the-World Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
Figure 96: Rest-of-the-World Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
Figure 97: Rest-of-the-World Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
Figure 98: Rest-of-the-World Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
Figure 99: Rest-of-the-World Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
Figure 100: Rest-of-the-World Brain Disease Modalities and Software Market (by Region), $Million, 2021 and 2031
Figure 101: Latin America Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 102: Middle East and Africa Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 103: Partnerships, Alliances, and Business Expansions (by Company), January 2018-December 2021
Figure 104: Funding Activities (by Company), January 2018-December 2021
Figure 105: New Offerings (by Company), January 2018-December 2021
Figure 106: Mergers and Acquisitions (by Company), January 2018-December 2021
Figure 107: Mergers and Acquisitions (by Company), January 2018-December 2021
Figure 108: Global Brain Disease Modalities and Software Market, Company Revenue Share Analysis, $Million, 2021
Figure 109: United Imaging Healthcare Co., Ltd.: Overall Product Portfolio
Figure 110: Koninklijke Philips N.V.: Overall Product Portfolio
Figure 111: Koninklijke Philips N.V.: Overall Financials, $Million, 2018-2020
Figure 112: Koninklijke Philips N.V.: Net Revenue (by Segment), $Million, 2018-2020
Figure 113: Koninklijke Philips N.V.: Net Revenue (by Region), $Million, 2018-2020
Figure 114: Koninklijke Philips N.V.: R&D Expenditure, $Million, 2018-2020
Figure 115: General Electric Company: Overall Product Portfolio
Figure 116: General Electric Company: Overall Financials, $Million, 2018-2020
Figure 117: General Electric Company: Net Revenue (by Segment), $Million, 2018-2020
Figure 118: General Electric Company: Net Revenue (by Region), $Million, 2018-2020
Figure 119: General Electric Company: R&D Expenditure, $Million, 2018-2020
Figure 120: Canon, Inc.: Overall Product Portfolio
Figure 121: Canon, Inc.: Overall Financials, $Million, 2018-2020
Figure 122: Canon, Inc.: Net Revenue (by Segment), $Million, 2018-2020
Figure 123: Canon, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 124: Canon, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 125: Siemens Healthineers AG: Overall Product Portfolio
Figure 126: Siemens Healthineers AG: Overall Financials, $Million, 2019-2021
Figure 127: Siemens Healthineers AG: Net Revenue (by Segment), $Million, 2019-2021
Figure 128: Siemens Healthineers AG: Net Revenue (by Region), $Million, 2019-2021
Figure 129: Siemens Healthineers AG: R&D Expenditure, $Million, 2019-2021
Figure 130: Vuno Co., Ltd.: Product Portfolio
Figure 131: Fujifilm Holdings Corporation: Product Portfolio
Figure 132: Fujifilm Holdings Corporation: Overall Financials, $Million, 2018-2020
Figure 133: Fujifilm Holdings Corporation: Net Revenue (by Segment), $Million, 2018-2020
Figure 134: Fujifilm Holdings Corporation: Net Revenue (by Region), $Million, 2018-2020
Figure 135: Fujifilm Holdings Corporation: R&D Expenditure, $Million, 2018-2020
Figure 136: Aspect Imaging: Product Offerings
Figure 137: IXICO: Product Portfolio
Figure 138: IXICO: Overall Financials, $Million, 2019-2021
Figure 139: IXICO (by Region), $Million, 2020-2021
Figure 140: IXICO: R&D Expenditure, $Million, 2019-2021
Figure 141: QMENTA: Product Portfolio
Figure 142: Cortechs.ai: Product Portfolio
Figure 143: Quantib: Product Portfolio
Figure 144: Brainomix: Product Portfolio
Figure 145: Qure.AI: Product Portfolio
Figure 146: Imaging Biometrics, LLC: Product Portfolio
Figure 147: A.I. Analysis, Inc.: Product Portfolio
Figure 148: Global Brain Disease Modalities and Software Market: Research Methodology
Figure 149: Primary Research
Figure 150: Secondary Research
Figure 151: Data Triangulation
Figure 152: Global Brain Disease Modalities and Software Market Research Process
Figure 153: Assumptions and Limitations
List of Tables
Table 1: Key Challenges and Possible Solutions for Players in the Global Brain Disease Modalities and Software Market
Table 2: Global Brain Disease Modalities and Software Market, Quarterly Key Developments Analysis, January 2018-December 2021
Table 3: Global Brai